Michel Detheux - 18 Apr 2022 Form 4 Insider Report for iTeos Therapeutics, Inc. (ITOS)

Role: Chief Executive Officer
Signature: /s/ Adi Osovsky, as Attorney-in-Fact
Issuer symbol: ITOS
Transactions as of: 18 Apr 2022
Net transactions value: -$317,885
Form type: 4
Filing time: 19 Apr 2022, 19:59:48 UTC
Previous filing: 22 Mar 2022
Next filing: 10 Mar 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ITOS	Common Stock	Options Exercise	$48,645	+11,500	+44%	$4.23	37,763	18 Apr 2022	Direct
transaction	ITOS	Common Stock	Sale	$365,453	-11,467	-30%	$31.87	26,296	18 Apr 2022	Direct	F1
transaction	ITOS	Common Stock	Sale	$1,077	-33	-0.13%	$32.64	26,263	18 Apr 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ITOS	Stock Option (Right to Buy)	Options Exercise	$0	-11,500	-7.4%	$0.000000	144,464	18 Apr 2022	Common Stock	11,500	$4.23	Direct	F2
holding	ITOS	Stock Option (Right to Buy)						185,000	18 Apr 2022	Common Stock	185,000	$4.23	By MG3A	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
F2	25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.

Content

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $31.39 to $32.37, inclusive. The reporting person undertakes to provide to iTeos Therapeutics, Inc., any security holder of iTeos Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

25% of the shares subject to the stock option vested on May 1, 2021. Thereafter, 1/48 of the shares subject to the stock option vest on a monthly basis, subject to the reporting person's continuous service relationship with the Issuer through each applicable vesting date.